Related Experiment Video
Updated: Jul 19, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid lowering therapy in the elderly: is there a benefit?
Kallirroi J Kalantzi1, Haralampos J Milionis, Dimitri P Mikhailidis
1Department of Cardiology, School of Medicine, University of Ioannina, 451 10 Ioannina, Greece.
Current Pharmaceutical Design
|November 1, 2006
Summary
Lipid-lowering treatment, particularly statins, shows promise for elderly cardiovascular disease (CVD) patients. Individualized treatment decisions are crucial, with further trials needed for optimal management of older adults at risk.
Area of Science:
- Gerontology
- Cardiology
- Pharmacology
Background:
- Aging populations increase healthcare burdens, with advanced age being a significant cardiovascular disease (CVD) risk factor.
- Established lipid-lowering treatments, primarily statins, have proven efficacy and safety, though trials often excluded older adults.
- Elderly individuals face a higher absolute risk of CVD, suggesting potential for substantial treatment benefits.
Purpose of the Study:
- To review modifiable cardiovascular risk factors in the elderly.
- To discuss findings from major clinical studies on lipid-lowering treatments in older populations.
- To explore considerations for lipid-lowering therapy in elderly patients.
Main Methods:
- Review of large-scale, randomized controlled trials (e.g., PROSPER, HPS) with elderly participants.
- Analysis of subgroup data from major cardiovascular trials.
- Survey of cardiovascular risk factors and treatment considerations in aging individuals.
Main Results:
- Evidence supports considering statin therapy in the elderly based on subgroup analyses and specific trials.
- Elderly populations have a greater absolute risk of CVD, implying significant benefits from effective treatment.
- Underevaluation and undertreatment of hypercholesterolemia are noted issues in the elderly.
Conclusions:
- Treatment decisions for hypercholesterolemia in the elderly should be individualized, considering risk, health status, and patient preferences.
- Further prospective randomized trials are necessary to guide clinical practice for older adults with increased atherosclerotic risk.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...